Urinary Disorder TRIZ Cases
- Migalastat Dosing for Fabry Disease With Severe Renal Impairment
Adjusted migalastat dosing intervals help Fabry patients with severe renal impairment or dialysis maintain α-Gal A activity and reduce renal substrate buildup.
- Belzutifan-Lenvatinib Combination for Refractory RCC Angiogenesis
Dual HIF-2α and VEGF-pathway blockade addresses refractory RCC after prior therapy, reducing tumor volume and extending progression-free survival.
- Asparagine Synthetase Inhibition for ADPKD Cyst Growth Control
Targeting ASNS and related metabolic pathways disrupts glutamine use and fatty acid synthesis to slow renal and liver cyst growth in ADPKD.
- Migalastat Dosing for Fabry Renal Impairment and Proteinuria
Oral migalastat stabilizes renal function in Fabry patients with renal impairment while lowering lyso-Gb3 and increasing α-Gal A activity.
- Herbal Composition for Cardiorenal Syndrome and Heart Failure
A multi-herb composition targets qi deficiency, blood stasis, and fluid retention to improve cardiorenal syndrome and heart failure outcomes.
- Mixed Herbal Extract Composition for Androgen-Pathway BPH Treatment
Alpha blockers and androgen inhibitors can cause temporary relief or sexual side effects; mixed Curcumae and Syzygii extracts target BPH pathways.
- Migalastat Chaperone Therapy for Fabry Renal Impairment
Migalastat stabilizes mutant α-Gal A and renal function in Fabry patients with mild to moderate renal impairment.